SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 821.28 |
Enterprise Value ($M) | n/a |
Book Value ($M) | 95.23 |
Book Value / Share | 2.27 |
Price / Book | n/a |
NCAV ($M) | 81.11 |
NCAV / Share | 1.93 |
Price / NCAV | n/a |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.72 |
Return on Assets (ROA) | -0.61 |
Return on Equity (ROE) | -0.74 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.02 |
Current Ratio | 4.02 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 111.49 |
Assets | 125.61 |
Liabilities | 30.38 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | LSP 7 Cooperative UA | 13.80 | 7.99 | |
13G/A | Bvcf Iv, L.p. | 5.05 | 5.88 | |
13G/A | Brunnur vaxtarsjodur slhf | 0.00 | -100.00 | |
13G | Pivotal bioVenture Partners Fund I, L.P. | 5.20 | 6.98 | |
13G/A | Novartis Bioventures Ltd | 4.70 | -21.32 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
3,011 | 34,552 | 8.71 | |
3,748 | 37,344 | 10.04 | |
5,873 | 51,663 | 11.37 | |
2,835 | 40,760 | 6.96 | |
(click for more detail) |
Similar Companies | |
---|---|
NKGN – NKGen Biotech, Inc. | NRIX – Nurix Therapeutics, Inc. |
NTLA – Intellia Therapeutics, Inc. | OCUL – Ocular Therapeutix, Inc. |
OKUR – OnKure Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io